ZVSA Quote, Financials, Valuation and Earnings

Chimerix has a net margin of -- compared to ZyVersa Therapeutics's net margin of -40270.18%. ZyVersa Therapeutics's return on equity of -- beat Chimerix's return on equity of -56.65%.

ZyVersa Therapeutics has a consensus price target of $70.00, signalling upside risk potential of 3305.42%. On the other hand Chimerix has an analysts' consensus of $8.54 which suggests that it could grow by 0.24%. Given that ZyVersa Therapeutics has higher upside potential than Chimerix, analysts believe ZyVersa Therapeutics is more attractive than Chimerix.

ZyVersa Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Chimerix has a beta of -0.176, suggesting its less volatile than the S&P 500 by 117.551%.

ZyVersa Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZyVersa Therapeutics pays -- of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend.

ZyVersa Therapeutics quarterly revenues are --, which are smaller than Chimerix quarterly revenues of $57K. ZyVersa Therapeutics's net income of -$2.4M is higher than Chimerix's net income of -$23M. Notably, ZyVersa Therapeutics's price-to-earnings ratio is -- while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics is -- versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to ZyVersa Therapeutics's net margin of -49.65%. ZyVersa Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

ZyVersa Therapeutics has a consensus price target of $70.00, signalling upside risk potential of 3305.42%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 48.6%. Given that ZyVersa Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe ZyVersa Therapeutics is more attractive than NovaBay Pharmaceuticals.

ZyVersa Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

ZyVersa Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZyVersa Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

ZyVersa Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. ZyVersa Therapeutics's net income of -$2.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, ZyVersa Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Omeros has a net margin of -- compared to ZyVersa Therapeutics's net margin of --. ZyVersa Therapeutics's return on equity of -- beat Omeros's return on equity of --.

ZyVersa Therapeutics has a consensus price target of $70.00, signalling upside risk potential of 3305.42%. On the other hand Omeros has an analysts' consensus of $36.00 which suggests that it could grow by 349.44%. Given that ZyVersa Therapeutics has higher upside potential than Omeros, analysts believe ZyVersa Therapeutics is more attractive than Omeros.

ZyVersa Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omeros has a beta of 2.352, suggesting its more volatile than the S&P 500 by 135.194%.

ZyVersa Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZyVersa Therapeutics pays -- of its earnings as a dividend. Omeros pays out -- of its earnings as a dividend.

ZyVersa Therapeutics quarterly revenues are --, which are smaller than Omeros quarterly revenues of --. ZyVersa Therapeutics's net income of -$2.4M is higher than Omeros's net income of -$32.2M. Notably, ZyVersa Therapeutics's price-to-earnings ratio is -- while Omeros's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics is -- versus -- for Omeros. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to ZyVersa Therapeutics's net margin of -2357.27%. ZyVersa Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

ZyVersa Therapeutics has a consensus price target of $70.00, signalling upside risk potential of 3305.42%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1200.63%. Given that ZyVersa Therapeutics has higher upside potential than Palatin Technologies, analysts believe ZyVersa Therapeutics is more attractive than Palatin Technologies.

ZyVersa Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

ZyVersa Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ZyVersa Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

ZyVersa Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. ZyVersa Therapeutics's net income of -$2.4M is higher than Palatin Technologies's net income of -$2.4M. Notably, ZyVersa Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ZyVersa Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.